COMMON BRAND NAME(S): Mycifradin
GENERIC NAME(S): NEOMYCIN SULFATE
Description: Neomycin interferes w/ bacterial protein synthesis by binding to 30S ribosomal subunits thereby inhibiting bacterial growth
Pharmacokinetics:
Absorption: Poorly absorbed from the GI tract. Time to peak plasma concentration: 1-4 hr (oral).
Distribution: Low concentrations in intestinal wall and muscles. Volume of distribution: 0.36 L/kg. Plasma protein binding: ≤30%.
Metabolism: Undergoes minimal hepatic metabolism.
Excretion: Via faeces (approx 97% of an oral dose, as unchanged drug); via urine (30-50% of absorbed drug, unchanged). Plasma half-life: 2-3 hr.